Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Study sponsor: Veru Inc. · VERU
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-01-09Actual
Enrollment · participants52Actual
Source updated2024-01-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.